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The protein tyrosine phosphatase Shp-2 regulates RhoA activity
Simone M. Schoenwaelder*, Leslie A. Petch†, David Williamson*,
Randy Shen‡, Gen-Sheng Feng‡ and Keith Burridge†§
Remodeling of filamentous actin into distinct
arrangements is precisely controlled by members of the
Rho family of small GTPases [1]. A well characterized
member of this family is RhoA, whose activation results
in reorganization of the cytoskeleton into thick actin
stress fibers terminating in integrin-rich focal adhesions
[2]. Regulation of RhoA is required to maintain
adhesion in stationary cells, but is also critical for cell
spreading and migration [3]. Despite its biological
importance, the signaling events leading to RhoA
activation are not fully understood. Several independent
studies have implicated tyrosine phosphorylation as a
critical event upstream of RhoA [4]. Consistent with this,
our recent studies have demonstrated the existence of a
protein tyrosine phosphatase (PTPase), sensitive to the
dipeptide aldehyde calpeptin, acting upstream of RhoA
[5]. Here we identify the SH2 (Src homology region 2)-
containing PTPase Shp-2 as a calpeptin-sensitive
PTPase, and show that calpeptin interferes with the
catalytic activity of Shp-2 in vitro and with Shp-2
signaling in vivo. Finally, we show that perturbation of
Shp-2 activity by a variety of genetic manipulations
results in raised levels of active RhoA. Together, these
studies identify Shp-2 as a PTPase acting upstream of
RhoA to regulate its activity and contribute to the
coordinated control of cell movement. 
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Results and discussion
Activation of the small GTPase RhoA induces a number of
morphological events including the promotion of stress
fibers, an increase in focal adhesions and cell contractility
[2]. Serum-starved Swiss 3T3 fibroblasts treated with
calpeptin undergo actin reorganization reminiscent of a
RhoA phenotype ([5], and Figure 1a). Our previous studies
have shown that calpeptin-mediated cytoskeletal effects
are induced through inhibition of one or more PTPase(s)
situated upstream of RhoA [5]. To determine if calpeptin-
sensitive PTPase(s) regulate RhoA activity, we constructed
a glutathione S-transferase (GST) fusion protein compris-
ing the RhoA-binding domain (RBD) of Rhotekin (an
effector for RhoA), similar to that described previously [6].
This GST fusion protein specifically binds to the active
GTP-bound form of RhoA. Analysis of cell lysates treated
with calpeptin (100 µg/ml) revealed that this peptide pro-
motes the accumulation of active (GTP-bound) RhoA
(Figure 1b), confirming that calpeptin increases the level
of active RhoA. Similar studies examining the effect of
calpeptin on the activity of other Rho-family GTPases
revealed no changes in GTP loading of either Rac or
Cdc42 (Figure 1b), demonstrating that calpeptin-sensitive
PTPase(s) specifically modulate RhoA activity.
To identify potential calpeptin-sensitive PTPase(s)
responsible for regulation of RhoA, we developed an
immobilized form of this peptide inhibitor (Figure 2a).
Initial analysis of overall PTPase activity precipitated with
immobilized calpeptin, using an in-gel PTPase assay,
revealed two major PTPases of ~70 and 120–130 kDa
(data not shown). Only the PTPase activity migrating at
Figure 1
Calpeptin-sensitive PTPase(s) regulate the activity of RhoA. (a) Swiss
3T3 fibroblasts were serum-starved for 24 h, to induce disassembly of the
cytoskeleton [5]. Cells were incubated with serum-free medium in the
presence or absence of calpeptin (100 µg/ml) for 30 min, and stained for
actin with rhodamine-conjugated phalloidin. (b) The levels of active RhoA,
Rac or Cdc42 in REF-52 fibroblasts treated with vehicle alone (C) or
100 µg/ml calpeptin (CP) (30 min) were analyzed by precipitating GTP-
bound RhoA with GST–RBD, or GTP-bound Rac and Cdc42 using
GST–PBD (see Materials and methods). Proteins precipitating with GST
fusion proteins were analyzed by immunoblotting with monoclonal
antibodies recognizing RhoA, Rac or Cdc42.
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70 kDa specifically bound to immobilized calpeptin, and
not to the control resin. Immunoblot analysis demon-
strated that the calpeptin-bound activity migrating at
approximately 70 kDa was Shp-2, a previously described
SH2-containing PTPase [7,8]. Further analysis confirmed
that Shp-2 bound to immobilized calpeptin but not to
control beads (Figure 2b), and also demonstrated that
binding was significantly reduced in the presence of
soluble calpeptin (data not shown), confirming the associa-
tion of Shp-2 with this peptide. Additional immunoblot
analysis of calpeptin-binding proteins revealed that immo-
bilized calpeptin did not precipitate PTPα or PTP-1B
(Figure 2b). We also assessed the ability of the hematopoi-
etic-specific Shp-1, which belongs to the family of SH2-
containing PTPases, to associate with immobilized
calpeptin. Despite its similarity to Shp-2, we could not
detect any binding of this PTPase to the immobilized
peptide (Figure 2b). While these studies do not rule out
the possibility that other PTPases may associate with
calpeptin, they do identify Shp-2 as a potential calpeptin-
sensitive PTPase. 
To demonstrate that the binding of calpeptin to Shp-2 has
physiological consequences, we analyzed the effect of this
inhibitor on Shp-2 signaling. In vitro PTPase assays using a
GST fusion protein comprising the catalytic domain of Shp-2
were performed in the presence or absence of increasing
amounts of calpeptin. We found the effect of calpeptin to
be dose-dependent, with 100 µg/ml of calpeptin decreasing
activity of this PTPase by approximately 40%, whereas
higher concentrations (1.0 mg/ml) inhibited Shp-2 activity
by approximately 90% (Figure 2c). The ability of calpeptin
to inhibit Shp-2 PTPase activity in vivo was also examined,
by analyzing the effect of this inhibitor on established Shp-2
signaling pathways. Previous studies have shown that abro-
gation of this PTPase results in modulation of Jun N-termi-
nal kinase (JNK) and extracellular signal-regulated kinase
(ERK) signaling [9]. Examination of calpeptin-treated cells
for JNK activation revealed a rise in the phosphorylation of
JNK (consistent with its activation), in both HeLa cells
(data not shown) and REF-52 fibroblasts (Figure 2d),
similar to the elevated JNK activity seen in Shp-2 mutant
cells [9]. In contrast to its effect on JNK activity, Shp-2 has
been reported to reduce and/or delay the level of ERK acti-
vation in response to growth factors or phorbol myristoyl
acetate (PMA) [9]. Consistent with this, REF-52 fibroblasts
treated with calpeptin show a reduction in sustained ERK
activation in response to PMA (see Supplementary mater-
ial). These findings are consistent with calpeptin’s ability to
inhibit Shp-2. 
The observations presented above raise the possibility that
Shp-2 may be the calpeptin-sensitive PTPase involved in
the regulation of RhoA activity. To investigate this
hypothesis, we analyzed the morphology and level of
RhoA activity in embryonic fibroblasts derived from mice
with a targeted disruption in exon 3 of the Shp-2 gene
(Shp-2∆46-110). These cells express a truncated Shp-2 lacking
its amino-terminal SH2 domain, at a greatly reduced level
when compared to the full-length wild-type PTPase [9].
Thus far, evidence suggests that the ∆46-110 Shp-2 muta-
tion might behave as a loss-of-function mutant in cells.
Comparison of these fibroblasts with wild-type cells
revealed an increase in the level of GTP-bound RhoA in
the mutant (Shp-2∆46-110)-expressing cells (Figure 3a, left
panels), concomitant with an increase in F-actin staining
[10]. Re-expression of wild-type Shp-2 in Shp-2∆46-110
mutant cells (Shp-2rescue) decreased RhoA–GTP levels
when compared with expression of vector alone (Shp-2∆46-110;
Figure 3a, middle panels) and reduced the level of F-actin
staining in these cells (see Supplemetary material). Fur-
thermore, Shp-2∆46-110 fibroblasts were less responsive to
changes in actin reorganization (see Supplementary mater-
ial) and Rho–GTP levels (Figure 3b, third and fourth
panels) when challenged with calpeptin, an effect which
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Figure 2
Identification of Shp-2 as a calpeptin-sensitive PTPase. (a) The
structure of immobilized calpeptin. (b) Whole cell lysates (TL)
prepared from Jurkat cells were incubated with control resin (C) or
immobilized calpeptin (CP), and precipitated proteins analyzed by
immunoblotting [5] with monoclonal antibodies directed against Shp-2,
PTPα, Shp-1 and PTP-1B. (c) The effect of calpeptin on the PTPase
activity of Shp-2 was examined by in vitro PTPase assays using a GST
fusion protein comprising the catalytic domain of Shp-2. Assays were
performed in the presence or absence of calpeptin (0.1–1.0 mg/ml),
within the linear range with respect to PTPase activity. Phosphatase
activity is expressed as a percentage of control (DMSO vehicle alone)
and reflects the mean ± SD from three independent experiments.
(d) REF-52 fibroblasts were treated with vehicle alone (C) or
100 µg/ml calpeptin (CP) (30 min). Alternatively, Shp-2WT (wild type)
or Shp-2∆46-110 fibroblasts were left untreated. Whole cell lysates were
analyzed for JNK activation by immunoblotting [5] with an activation-
specific antibody against SAPK/JNK.
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was restored by rescue with wild type Shp-2 (see Supple-
mentary material, and Figure 3b, third and fourth panels).
This suggests that Shp-2 inhibition is mediating the
calpeptin-induced effects on RhoA activity. We also
examined RhoA activity levels in CHO cells transiently
transfected with dominant-negative Shp-2 (CHOSH2).
Consistent with our previous results in mouse fibroblasts,
CHOSH2 cells exhibited elevated RhoA-GTP levels
(Figure 3a, right panels), when compared with cells trans-
fected with vector alone (CHOvector). As with Shp-2∆46-110
mutant cells, the response of CHOSH2 cells to calpeptin
was significantly reduced (Figure 3b, first and second
panels). These results support our hypothesis that Shp-2
negatively regulates RhoA activity.
The concerted actions of Rho proteins on the arrangement
of F-actin influence numerous normal and pathological
events including embryonic development, wound healing
and tumor metastasis [1]. Many of these processes rely
critically on cell migration. RhoA is required for the char-
acteristic formation and maintenance of stress fibers and
focal adhesions, but it is also required to maintain a certain
level of cell adhesion during cell movement [3]. Concor-
dant with this, our studies show that inhibition of Shp-2
effectively increases the basal level of active RhoA,
thereby increasing cell adhesion. Excessive levels of cell
adhesion would be expected to negatively affect cell
motility, preventing cells from releasing their contact sites
as they attempt to migrate across an extracellular matrix.
This hypothesis is consistent with several studies that
have investigated the biological function of Shp-2 [10–16].
Animals with dysfunctional Shp-2 die at mid-gestation
with severe defects in mesodermal patterning and body
organization [11]. These mutant embryos fail to undergo
morphogenetic movements at gastrulation [15,16]. Cells
derived from these embryos exhibit increased focal adhe-
sions, and decreased cell spreading and migration [10],
which is also consistent with an increase in RhoA activa-
tion. We suggest that abrogation of Shp-2 in these
embryos raises the basal level of RhoA activity, thereby
impairing migration and contributing to the observed
migration-based embryonic defects. 
We have shown that Shp-2 is an important regulatory com-
ponent upstream of the small GTPase RhoA. Although
our studies indicate that Shp-2 regulates RhoA, the sub-
strates that are dephosphorylated by Shp-2 are currently
under investigation. Interestingly, there is now a prece-
dent for the activation of guanine-nucleotide exchange
factors (GEF), which facilitate nucleotide exchange on
Rho family proteins, by tyrosine phosphorylation [4]. In
addition, tyrosine phosphorylation of GTPase-activating
proteins (GAPs), which stimulate the intrinsic GAP activ-
ity of small GTPases, have also been reported [17]. With
p190RhoGAP, however, increased tyrosine phosphoryla-
tion is correlated with increased GAP activity, and conse-
quently decreased RhoA–GTP levels [18].
Ligation of several growth factor receptors results in a loss
of stress fibers and focal adhesions, indicative of decreased
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Figure 3
Shp-2 regulates the level of RhoA activity.
(a) The level of active RhoA was measured
(as described in Materials and methods) in
Shp-2WT or Shp-2∆46-110 fibroblasts (left),
Shp-2∆46-110 fibroblasts transfected with
vector alone (Shp-2∆46-110) or wild type
Shp-2 (Shp-2rescue) (middle), or CHO cells
transiently transfected with vector alone
(CHOvector) or dominant-negative Shp-2
(CHOSH2) (right). Densitometric quantitation
of immunoblots corrected for protein loading
is presented as relative fold increase
(histograms). (b) Shp-2 represents a major
mediator through which calpeptin induces
effects on RhoA activity. First and second
panels, CHO cells were transiently
transfected with either vector alone
(CHOvector) or dominant-negative Shp-2
(CHOSH2). Eighteen to twenty-four hours
post-transfection, cells were challenged with
vehicle alone (C) or 100 µg/ml calpeptin
(CP) for 30 min (n = 2). Third and fourth
panels, Shp-2∆46-110 or Shp-2rescue
fibroblasts were challenged with vehicle
alone (C) or 100 µg/ml calpeptin (CP) for
30 min (n = 3). Cell lysates from each
experiment were prepared and assayed for
Rho–GTP levels. Densitometric quantitation
of immunoblots corrected for protein loading
is presented as fold increase over control-
treated cells.
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RhoA activity [4]. One mechanism contributing to this
effect is suggested by our findings here that Shp-2 nega-
tively regulates RhoA activity. We envisage a model
wherein recruitment of Shp-2 by growth factor receptors
brings this PTPase into close proximity with a critical
RhoA GEF (see Supplementary material). Dephosphory-
lation of the GEF by Shp-2 downregulates its activity,
resulting in decreased RhoA–GTP levels, in turn leading
to a loss of stress fibers and focal adhesions, and effects on
the motile state of the cell.
Materials and methods
Cell lines, antibodies and constructs
Shp-2 wild-type (Shp-2WT), mutant (Shp-2∆46-110) and Shp-2∆46-110
rescued with wild-type Shp-2 (Shp-2rescue) embryonic fibroblast cell
lines were established from E9.5 mouse embryos as described ([9,10]
and Supplementary material). Transient transfection of CHO cells was
carried out using LipofectAMINE PLUS reagent (Gibco BRL), accord-
ing to manufacturers instructions (see Supplementary material). The
plasmid containing cDNA encoding Shp-2 SH2 domains (dominant
negative) was generated as previously described [19]. Activation-spe-
cific anti-SAPK/JNK polyclonal antibody was from New England
BioLabs. Phospho-specific anti-ERK monoclonal antibody was from
UBI. All other monoclonal antibodies were purchased from Transduc-
tion Laboratories.
Preparation and use of immobilized calpeptin 
The reactive portion of calpeptin (Leu–Nle–CHO) was synthesized
commercially (SynPep Corporation), and coupled to Affi-Gel10 resin
(0.5 mg peptide per ml resin) (BioRad). Affi-Gel10 control resin was
prepared by blocking active esters, according to the manufacturer’s
instructions. Cells lysed in a Triton X-100-containing lysis buffer
(10 mM Tris pH 7.6, 150 mM NaCl, 1% Triton X-100, 2 mM MgCl2,
2 mM EGTA, 0.1 mM DTT, 10 µg/ml aprotinin) were incubated with
immobilized calpeptin or control resin for 2 h at 4°C, and beads
washed with lysis buffer. Precipitated proteins were analyzed by
SDS–PAGE and immunoblot analysis.
In vitro PTPase assays
The catalytic domain of wild-type Shp-2 was generated by PCR amplifi-
cation of a cDNA fragment coding for amino acids 217–585 of Shp-2
and cloning into pGex2T vector via BamH1 and EcoR1. The resulting
GST fusion protein was expressed in BL21 cells and purified as
described previously [5]. PTPase assays were performed essentially as
described [20], using p-nitrophenyl phosphate as a substrate. 
Assay for GTP-bound RhoA, Rac and Cdc42
The RhoA-binding domain (RBD) of Rhotekin (amino acids 7–89) was
amplified from cDNA prepared from BALB 3T3 mRNA, and cloned into
the pGEX-2T vector. The Rac/Cdc42-binding domain of PAK (PBD)
was a kind gift from R.A. Cerione (Cornell University, New York). Both
RBD and PBD were expressed as GST fusion proteins in BL21 cells.
The levels of GTP-bound RhoA, Rac and Cdc42 in cell lysates were
measured as described previously [6,21].
Supplementary material
Supplementary material including production of cell lines, figures
depicting the effect of calpeptin on ERK activity and cell morphology
and a proposed model for Shp-2-mediated regulation of RhoA, is avail-
able at http://current-biology.com/supmat/supmatin.htm.
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